Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

614
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
614

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.

Nature·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review.

Journal of investigative surgery : the official journal of the Academy of Surgical Research·2026
Same author

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

Haematologica·2026
Same author

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report.

NPJ precision oncology·2026
Same author

Will I make it home again?

The oncologist·2026

Related Experiment Video

Updated: Nov 6, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.2K

[Precision diagnostics and therapy in hematological malignancies].

Eva Hellström Lindberg1, Lucia Cavelier2, Jörg Cammenga3

  • 1professor, överläkare, Karolinska institutet och Karolinska universitetssjukhuset.

Lakartidningen
|May 11, 2021
PubMed
Summary
This summary is machine-generated.

Precision diagnostics and targeted therapies are advancing in hematologic malignancies, driven by genetic insights from blood and bone marrow analysis. New sequencing techniques and drug development promise improved patient outcomes.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Related Experiment Videos

Last Updated: Nov 6, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Area of Science:

  • Hematology
  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Hematologic malignancies have benefited from early adoption of precision diagnostics and therapies.
  • Accessibility of blood and bone marrow facilitates genetic analysis and in vitro drug testing.
  • Targeting specific driver mutations, such as ABL1, JAK2, and FLT3, has led to effective treatments.

Purpose of the Study:

  • To review the evolution and current state of precision diagnostics and therapy in hematologic malignancies.
  • To highlight the role of genetic analysis in diagnosis, prognosis, and treatment selection.
  • To discuss emerging technologies and future directions in the field.

Main Methods:

  • Review of current literature and clinical practices in hematologic oncology.
  • Discussion of established and emerging genetic sequencing technologies (gene panels, whole genome/transcriptome).
  • Overview of targeted therapies and their clinical applications.

Main Results:

  • Precision diagnostics, including gene panel sequencing, are integral to clinical hematology.
  • Targeted inhibitors (e.g., ABL1, JAK2, FLT3) have transformed treatment for specific leukemias and neoplasms.
  • Emerging sensitive techniques for minimal residual disease monitoring are under development.
  • Whole genome and transcriptome sequencing are being evaluated for future diagnostic use.

Conclusions:

  • Hematologic malignancies are at the forefront of precision medicine due to accessible samples and targetable mutations.
  • Continued advancements in genetic sequencing and targeted therapies are expected to further improve patient care.
  • The development pipeline for targeted therapies in hematology is robust, with many agents in clinical trials.